(May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast an analyst meeting it is hosting on Wednesday, May 26, in conjunction with the Paris Course on Revascularization (PCR), the largest interventional cardiology conference in Europe. The meeting is scheduled to begin at 11:00 a.m. ET (5:00 p.m. Paris time) and conclude at approximately 12:30 p.m. ET (6:30 p.m. Paris time).

Presentations will be made by the following Boston Scientific officials:

Larry Best, Senior Vice President and Chief Financial Officer

Paul LaViolette, Senior Vice President and Group President, Cardiovascular

Mary Russell, M.D., F.A.C.C., Senior Vice President and Chief Medical Officer for Cardiovascular Clinical Sciences

The meeting will include an update on the TAXUS Clinical Program, particularly the results of the TAXUS VI clinical trial, which will be announced at PCR. The meeting will also include an update on Boston Scientific's cardiovascular business, including sales of its TAXUS™ Express²™ paclitaxel-eluting coronary stent system. A question and answer session will follow these presentations.

This meeting is being webcast and can be accessed at Boston Scientific's website, www.bostonscientific.com.

The webcast is also being distributed over CCBN's Investor Distribution Network via two locations: CCBN's Individual Investor Center www.fulldisclosure.com, which is accessible to the public; and www.streetevents.com, CCBN's password-protected event management site for CCBN clients.

A replay of the webcast will be archived and available in the Webcast and Archives section of the Investor Relations site at www.bostonscientific.com beginning at approximately 3:00 p.m. ET on May 26 and running through June 25.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.